Johnson & Johnson starts Ebola vaccine trial in Sierra Leone

2015-10-09 15:23
iStock

iStock

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

New Brunswick - Johnson & Johnson has begun clinical trials for an Ebola vaccine in Sierra Leone.

The vaccine regimen is part of a new study being conducted in Sierra Leone's Kambia district, where some of the country's most recent Ebola cases have been reported.

The study, in development at subsidiary Janssen Pharmaceutical Cos, will evaluate safety and immune response within Sierra Leone's general population.

The company said Friday that the first volunteers have received the initial dose.

Johnson & Johnson, based in New Brunswick, New Jersey, said that there are separate studies being conducted in the US, Europe and Africa as part of the accelerated development plan to prevent Ebola outbreaks.

There is currently no licensed vaccine, treatment or cure for the Ebola virus.

Read more on:    johnson & johnson  |  sierra leone  |  ebola  |  west africa

Join the conversation!

24.com encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.

Inside News24

 
/News

Book flights

Compare, Book, Fly

Traffic Alerts
There are new stories on the homepage. Click here to see them.
 
English
Afrikaans
isiZulu

Hello 

Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.


Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Settings

Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.




Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.